ABVC BioPharma vs MediciNova
MediciNova reported revenue of $0 million in fiscal 2025, 1.3 times ABVC BioPharma's $0 million in fiscal 2025. ABVC BioPharma had an operating margin of -2416.0%, against -3242.5% at MediciNova.
Side by side
| ABVC BioPharma | MediciNova | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | −41.9% | — |
| Revenue growth a year, last 5 years | −9.7% | — |
| Gross margin | — | — |
| Operating margin | −2,416.0% | −3,242.5% |
| Net margin | −2,671.8% | −2,928.8% |
| Free cash flow | — | −$10M |
| Free cash flow margin | — | −2,395.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 72.2% | 0.0% |
| Last close | $0.88 | $1.27 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $1.7 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ABVC BioPharmaMediciNova
Operating margin
Percent of revenue
ABVC BioPharmaMediciNova
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ABVC BioPharmaMediciNova
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ABVC BioPharma and MediciNova pages.